---
figid: PMC10919760__ijo-64-04-05629-g02
figtitle: Targeted and immunotherapeutic agents screened in GC PDX and PDO models
organisms:
- NA
organisms_ner:
- Homo sapiens
pmcid: PMC10919760
filename: ijo-64-04-05629-g02.jpg
figlink: /pmc/articles/PMC10919760/figure/F3
number: F3
caption: Overview of targeted and immunotherapeutic agents screened in GC PDX and
  PDO models. The major signaling and crosstalk of Hedgehog, EGFR, HGF-MET, VEGF,
  JAK/STAT, Wnt and Hippo pathways are illustrated. Representative targets in GC and
  the corresponding targeted or immunotherapeutic agents are depicted. Drugs in the
  figure include small molecular inhibitors, monoclonal antibodies, nanobodies, CAR-T
  drugs, ADCs and natural products. Targeted agents include those that have been approved
  (colored in green), studied in clinical trials (colored in red) and in preclinical
  or early phase development (colored in purple) for the treatment of gastric cancer.
  SMO, smoothened, frizzled class receptor; Kif7, kinesin family member 7; Sufu, SUFU
  negative regulator of hedgehog signaling; Gli, GLI family zinc finger; CDK, cyclin-dependent
  kinase; EGFR, epidermal growth factor receptor; HER2, Erb-B2 receptor tyrosine kinase
  2; HGF, hepatocyte growth factor; MET, met proto-oncogene, receptor tyrosine kinase;
  AKT, AKT serine/threonine kinase; TSC1/2, TSC complex subunit 1/2; mTOR, mammalian
  target of rapamycin; P70S6K1, ribosomal protein S6 kinase B1; VEGFR, vascular endothelial
  growth factor receptor; FGFR2, fibroblast growth factor receptor 2; JAK, janus kinase;
  STAT, signal transducer and activator of transcription; APC, APC regulator of Wnt
  signaling pathway; MST, mitogen-activated protein kinase kinase kinase 10; PD-1,
  programmed cell death 1; PD-L1, programmed cell death ligand 1; YAP, yes-associated
  protein; PARP, poly ADP-ribose polymerase; ATR, ATM and Rad3 related protein; Wee1,
  Wee1 G2 checkpoint kinase; GC, gastric cancer; PDX, patient-derived xenograft; PDO,
  patient-derived organoid; CAR-T, chimeric antigen receptor T cell; ADC, antibody-drug
  conjugate
papertitle: Xenograft and organoid models in developing precision medicine for gastric
  cancer (Review)
reftext: Jiao Xu, et al. Int J Oncol. 2024 Apr;64(4).
year: '2024'
doi: 10.3892/ijo.2024.5629
journal_title: International Journal of Oncology
journal_nlm_ta: Int J Oncol
publisher_name: D.A. Spandidos
keywords: gastric cancer | patient-derived tumor xenografts | organoids | drug screening
  | precision medicine
automl_pathway: 0.9324659
figid_alias: PMC10919760__F3
figtype: Figure
redirect_from: /figures/PMC10919760__F3
ndex: ''
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC10919760__ijo-64-04-05629-g02.html
  '@type': Dataset
  description: Overview of targeted and immunotherapeutic agents screened in GC PDX
    and PDO models. The major signaling and crosstalk of Hedgehog, EGFR, HGF-MET,
    VEGF, JAK/STAT, Wnt and Hippo pathways are illustrated. Representative targets
    in GC and the corresponding targeted or immunotherapeutic agents are depicted.
    Drugs in the figure include small molecular inhibitors, monoclonal antibodies,
    nanobodies, CAR-T drugs, ADCs and natural products. Targeted agents include those
    that have been approved (colored in green), studied in clinical trials (colored
    in red) and in preclinical or early phase development (colored in purple) for
    the treatment of gastric cancer. SMO, smoothened, frizzled class receptor; Kif7,
    kinesin family member 7; Sufu, SUFU negative regulator of hedgehog signaling;
    Gli, GLI family zinc finger; CDK, cyclin-dependent kinase; EGFR, epidermal growth
    factor receptor; HER2, Erb-B2 receptor tyrosine kinase 2; HGF, hepatocyte growth
    factor; MET, met proto-oncogene, receptor tyrosine kinase; AKT, AKT serine/threonine
    kinase; TSC1/2, TSC complex subunit 1/2; mTOR, mammalian target of rapamycin;
    P70S6K1, ribosomal protein S6 kinase B1; VEGFR, vascular endothelial growth factor
    receptor; FGFR2, fibroblast growth factor receptor 2; JAK, janus kinase; STAT,
    signal transducer and activator of transcription; APC, APC regulator of Wnt signaling
    pathway; MST, mitogen-activated protein kinase kinase kinase 10; PD-1, programmed
    cell death 1; PD-L1, programmed cell death ligand 1; YAP, yes-associated protein;
    PARP, poly ADP-ribose polymerase; ATR, ATM and Rad3 related protein; Wee1, Wee1
    G2 checkpoint kinase; GC, gastric cancer; PDX, patient-derived xenograft; PDO,
    patient-derived organoid; CAR-T, chimeric antigen receptor T cell; ADC, antibody-drug
    conjugate
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - DHH
  - IHH
  - SHH
  - SMO
  - SMOX
  - EGFR
  - CARTPT
  - VEGFA
  - VEGFB
  - VEGFC
  - VEGFD
  - PGF
  - WNT1
  - WNT2
  - WNT2B
  - WNT3
  - WNT3A
  - WNT4
  - WNT6
  - WNT7A
  - WNT7B
  - WNT8A
  - WNT8B
  - WNT9A
  - WNT9B
  - WNT10A
  - WNT10B
  - WNT11
  - WNT16
  - WNT5A
  - WNT5B
  - SOAT1
  - STAT1
  - STAT2
  - STAT3
  - STAT4
  - STAT6
  - STAT5A
  - STAT5B
  - JAK1
  - JAK2
  - JAK3
  - TYK2
  - LRP5
  - LRP6
  - FZD1
  - FZD10
  - FZD2
  - FZD3
  - FZD4
  - FZD5
  - FZD6
  - FZD7
  - FZD8
  - FZD9
  - FGFR2
  - KIF7
  - SUFU
  - GLI3
  - GLI1
  - GLI2
  - HGF
  - IL6
  - SOS1
  - KRAS
  - HRAS
  - NRAS
  - ERBB4
  - KDR
  - FLT1
  - FLT4
  - CD36
  - FAT1
  - DVL1
  - DVL1P1
  - DVL2
  - DVL3
  - AXIN1
  - AXIN2
  - GSK3A
  - GSK3B
  - PIK3CA
  - PIK3CB
  - PIK3CD
  - PIK3CG
  - PIK3R3
  - PIK3R4
  - PIK3R5
  - PIK3R6
  - PIK3R1
  - PIK3R2
  - APC
  - PROC
  - CSNK1A1
  - MST1
  - STK4
  - STK3
  - MAP3K10
  - MPST
  - TAM
  - MSTO1
  - ZHX2
  - ARAF
  - BRAF
  - RAF1
  - AKT1
  - AKT2
  - AKT3
  - MAP2K1
  - TSC1
  - CCL26
  - TSC2
  - CD274
  - MAPK3
  - MAPK1
  - MTOR
  - RPTOR
  - SMN1
  - AZIN2
  - GADL1
  - CDKL1
  - CDKL2
  - CDKL3
  - CDKL4
  - CDKL5
  - CDK3
  - CDK4
  - CDK5
  - CDK6
  - CDK7
  - CDK8
  - CDK9
  - CDK10
  - CDK11A
  - CDK11B
  - CDK12
  - CDK13
  - CDK14
  - CDK15
  - CDK16
  - CDK17
  - CDK18
  - CDK19
  - CDK20
  - CDK1
  - CDK2
  - YAP1
  - CA3
  - ATR
  - ANTXR1
  - MMAB
  - SERPINA2
  - CHEK1
  - PARP1
  - COL11A2
  - PARP2
  - PARP3
  - PARP4
  - PARP6
  - PARP8
  - PARP9
  - PARP10
  - PARP11
  - PARP12
  - PARP14
  - PARP15
  - PARP16
  - TNKS
  - TNKS2
  - TIPARP
  - WEE1
  - vismodegib
  - crizotinib
  - regorafenib
  - lenvatinib
  - BEZ235
  - BYL719
  - sorafenib
  - palbociclib
  - everolimus
  - rapamycin
  - ADC
  - olaparib
  - veliparib
  - BMN673
  - PARP
  - adavosertib
---
